Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Obesity & Rheumatic Disease

Richard Quinn  |  December 9, 2016

“The treatment of obesity is particularly challenging,” Dr. Ritchlin adds. “The most important strategy is to cut down on caloric intake, a goal that is difficult to achieve and maintain. Additional approaches include medications and bariatric surgery.”

Dr. Ritchlin says he works with nutritionists in URMC’s Endocrinology Division to work with patients on weight loss and to emphasize to obese patients that they “play an active role in the treatment of their disease by losing weight.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Both Drs. Matteson and Ritchlin agree that a multi-disciplinary approach to obesity is key for rheumatologists.

“I don’t think there can be too many cooks in the kitchen,” Dr. Matteson says. “Attention to obesity and its health and social consequences is the responsibility of the entire society, and certainly of all caregivers, including primary care providers (PCPs) and rheumatologists.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

With so many proverbial cooks in the kitchen, it can be difficult for rheumatologists to know who should take the lead with a patient. Dr. Matteson says that should be handled on a case-by-case basis.

“I think it depends on the relationship the patient has with their physician,” he says. “In some cases, it is the rheumatologist who is quarterbacking the coordination of healthcare for their patients, and in others, the PCP takes the primary role. In either case, the engagement of all specialties with the patient is crucial.”

The rheumatologist also has to handle the topic of obesity delicately. The personal responsibility of an obese patient’s response to their condition must be emphasized, but delivered professionally. Discussions should focus on weight control and rheumatic disease activity control, highlighting the importance of physical activity for both conditions and keeping weight control “in the forefront of the patient’s health goals,” Dr. Matteson says.

“It is important to monitor weight change at serial visits, acknowledge any weight loss and help patients work through the various treatment options without being paternalistic or denigrating,” Dr. Ritchlin adds. “Working with a team as described above is the best approach so the patient does not feel isolated or frustrated.”

Preaching at patients would only frustrate them and, potentially, reduce the positive impact of education, follow-up and encouragement, Dr. Matteson says.

“We can’t just tell our patients what to do. We need to show them what the benefits of optimal body weight and physical activity are, and provide the resources for them to link to healthy living programs and activities.”


Richard Quinn is a freelance writer in New Jersey.

Page: 1 2 3 | Single Page
Share: 

Filed under:Conditions Tagged with:DietinflammationObesitypreventiveRheumatic Disease

Related Articles

    Psoriatic Arthritis & the Obese Patient

    November 6, 2022

    Estimates from the National Psoriasis Foundation indicate that more than 8 million people in the U.S. suffer from psoriasis and that approximately 30% of those individuals develop psoriatic arthritis (PsA).1 Given these statistics, roughly 2.4 million people in the country are likely affected by PsA. Moreover, patients with this systemic condition carry a higher-than-average burden…

    Mechanistic, Epidemiologic Clues Suggest Possible Link Between Obesity, Inflammation in Rheumatoid Arthritis

    October 11, 2016

    Obesity has an established systemic inflammatory component. Could that be a trigger for the inflammation seen in rheumatoid arthritis (RA) and other rheumatic diseases? Although there is no direct scientific evidence, both mechanistic and epidemiologic clues do give some intriguing suggestions of a possible link. “At first, we thought that fat was involved only in…

    Psoriatic Arthritis: A Look Back at Moll & Wright’s Landmark 1973 Paper

    May 17, 2019

    Psoriatic arthritis came to be viewed as a distinct disease entity with specific clinical features, genetics and pathophysiology only gradually. One important historic development in this transition was a 1973 paper written by a pair of researchers out of Leeds, England: John M. Moll, BSc, DM, and Verna Wright, MD, FRCP.1 Here we discuss the…

    Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium

    April 2, 2014

    Therapy with tumor necrosis factor inhibitors, nonsteroidal antiinflammatory drugs, ustekinumab in early stages of osteitis may halt molecular switching to bone-forming phenotype characteristic of SpA

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences